[{"Assets_0_Q3_USD":509237000.0,"CommonStockSharesOutstanding_0_Q3_shares":36840000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-82199000.0,"NetIncomeLoss_1_Q3_USD":-34584000.0,"NetIncomeLoss_3_Q3_USD":-68269000.0,"StockholdersEquity_0_Q3_USD":468395000.0,"EarningsPerShareBasic_1_Q3_USD":-0.94,"EarningsPerShareBasic_3_Q3_USD":-1.86,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":36813000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":36618000.0,"Ticker":"RGNX","CIK":"1590877","name":"REGENXBIO INC.","OfficialName":"REGENXBIO Inc. Common Stock","form":"10-Q","period":"20190930","fy":"2019.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1299022052.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20191105"}]